Extending FDA-approved cancer drug indications requires high patient numbers, study finds

A bro­ken em­bar­go on the high­est-pro­file ab­stracts at this year’s Eu­ro­pean So­ci­ety for Med­ical On­col­o­gy has forced the con­fer­ence or­ga­niz­er to re­lease da­ta from the

ORLANDO — Cryoablation without excision for low-risk, early-stage breast cancer may be an option for women over 60, 5-year follow-up results from the ICE3 trial

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes